⁶⁸Ga?DOTATOC?PET/MRI and¹¹C?5?HTP?PET/MRI are superior to⁶⁸Ga?DOTATOC?PET/CT for neuroendocrine tumour imaging

The present study aimed to assess gadoxetate disodium contrast-enhanced (CE) positron emission tomography (PET)/magnetic resonance imaging (MRI) with 68Ga-DOTATOC and 11C-5-Hydroxy-tryptophan (11C-5-HTP) in comparison iodine CE 68Ga-DOTATOC-PET/computed (CT) for neuroendocrine tumour imaging. Detection rate reader's confidence were evaluated each separate image volume: CE-CT, CE-MRI including diffusion-weighted imaging, 68Ga-DOTATOC-PET performed at PET/CT, PET/MRI 11C-5-HTP-PET, the three combined hybrid examinations 68Ga-DOTATOC-PET/MRI, 11C-5-HTP-PET/MRI 68Ga-DOTATOC-PET/CT. In 11 patients, 255 lesions depicted. depicted 72.5%, PET/CT 62.7%, 11C-5-HTP-PET 68.2% CE-CT 53% of lesions. (P < 0.001) = 0.02), MRI superior CT. 68Ga-DOTATOC-PET/MRI detected 92.5% 92% lesions, respectively, both outperformed 68Ga-DOTATOC-PET/CT (65%) 0.001). For liver metastasis alone was unsurpassed 0.01) lymph node diagnosis, 94%, 94% bone equally well 0.05) better than MRI. Reader's maximum standardised uptake value tumour-to-liver ratio approximately twice as high 11C-5-HTP. provided highest detection rates 68Ga-DOTATOC-PET/CT, mainly because component. contrast that